CareDx, Inc. is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers products, testing services, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients.
The VP of Specialty Oncology role serves as the Franchise Leader for NavDx across Head & Neck, GI, and Gynecologic cancers, with full accountability for strategy, brand marketing, market shaping, and pipeline. This leader owns the commercial and medical education ecosystem for NavDx, driving adoption, clinical integration, and long-term franchise value, while orchestrating upstream marketing (product lifecycle management, indication expansion), downstream marketing (brand strategy, targeting, messaging, selling directions), Medical Education, KOL engagement.
Core AccountabilitiesFranchise Strategy & P&L Ownership- Own the integrated franchise strategy across HPV-driven cancers aligned to long-term growth
- Accountable for volume, revenue, and market share performance
- Translate clinical evidence and market insights into strategic priorities and investments
- Shape lifecycle expansion, new indications, and guideline inclusion strategies
- Lead market shaping strategies to redefine standards of care in surveillance and MRD monitoring
- Partner with Medical Affairs to develop evidence generation and publication strategy that supports guideline inclusion, clinical adoption and payer coverage
- Establish NavDx as the reference standard across academic and community settings
- Lead indication strategy, value proposition, and positioning by tumor type
- Align evidence generation priorities with Medical Affairs and R&D
- Ensure strategy is grounded in unmet clinical need and differentiated value
- Lead downstream marketing teams responsible for campaigns, congress strategy, and field enablement
- Ensure translation of strategy into field-ready programs that accelerate adoption
- Provide strategic leadership to Medical Education teams
- Ensure compliant, high-impact engagement with multidisciplinary care teams and thought leaders
- Translate franchise strategy into field team priorities and targeting
- Partner with Sales, Training & Operations to ensure world-class sales execution and management cadence
- Partner with Operations and Finance to deliver forecasting, demand planning, and performance insights
- Act as single point of accountability for franchise alignment across functions
- Drive disciplined execution through data-driven decision making
- Represent the franchise in executive and strategic planning forums
- Advanced degree preferred (MBA, PhD, PharmD, MD)
- 12+ years in oncology, molecular diagnostics, or biopharma
- Proven franchise or portfolio leadership experience inclusive of brand marketing/management leadership
- Deep experience across upstream/downstream marketing and medical collaboration
- Strong matrix leadership and influence skills
- Led multiple product/indication launches as a Commercial lead
- Extensive experience developing and leading Market Shaping activities
- Extensive experience working with Medical Affairs on clinical trials, evidence generation and publications
- Enterprise mindset with full accountability
- Strategic clarity combined with operational rigor
- Collaborative leader with credibility across Sales and Medical
- High integrity with strong compliance orientation
Additional Details:
Every individual at CareDx has a direct impact on our collective mission to improve the lives of organ transplant patients worldwide. We believe in taking great care of our people, so they take even greater care of our patients.
Our competitive Total Rewards package for US Employees includes:
- Competitive base salary and incentive compensation
- Health and welfare benefits, including a gym reimbursement program
- 401(k) savings plan match
- Employee Stock Purchase Plan
- Pre-tax commuter benefits
- And more!
- Please refer to our page to view detailed benefits at https://caredx.com/company/careers
In addition, we have a Living Donor Employee Recovery Policy that allows up to 30 days of paid leave annually to a full-time employee who makes the selfless act of donating an organ or bone marrow.
With products that are making a difference in the lives of transplant patients today and a promising pipeline for the future, it’s an exciting time to be part of the CareDx team. Join us in partnering with transplant patients to transform our future together.
CareDx, Inc. is an Equal Opportunity Employer-vets/disabled, and participates in the E-Verify program. By proceeding with our application and submitting your information, you acknowledge that you have read our U.S. Personnel Privacy Notice and consent to receive email communication from CareDx. Certain jurisdictions require notice of how we use and protect your personal information. For more information, please read our Privacy Policy
The U.S. EEO posters are available here.
Note: We do not accept resumes from headhunters, placement agencies, or other suppliers that have not signed a formal agreement with us.
#LI-Remote
This is the anticipated base salary range for candidates who will work in Brisbane, California. The final salary offered to a successful candidate will be dependent on several factors that may include, but are not limited to, the type and length of experience within the job, the type and length of experience within the industry, education, etc. Base pay is one part of the Total Package that is provided to compensate and recognize employees for their work, and this role may be eligible for additional discretionary bonuses/incentives and restricted stock units. CareDx is a multi-state employer, and this salary range may not reflect positions that work in other states.
Skills Required
- Advanced degree (MBA, PhD, PharmD, MD)
- 12+ years in oncology, molecular diagnostics, or biopharma
- Proven franchise or portfolio leadership experience with P&L ownership
- Deep experience across upstream (indication strategy, evidence) and downstream (brand, campaigns) marketing
- Experience leading MSL, Medical Education, and Medical Affairs collaboration
- Experience managing sales leaders and translating strategy into sales priorities
- Strong matrix leadership, influence skills, and cross-functional collaboration experience
- Strategic clarity combined with operational rigor and data-driven decision making
- High integrity with strong compliance orientation
What We Do
CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions. NASDAQ:CDNA About AlloSure® AlloSure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. AlloSure is a clinical-grade, proprietary Next-Generation Sequencing (NGS) based test to detect donor-derived cell-free DNA (dd-cfDNA) in order to identify organ injury in kidney transplant recipients. AlloSure is analytically validated as a sensitive, specific, and precise measurement of dd-cfDNA. AlloSure detects active rejection (acute active ABMR, chronic active ABMR, or TCMR) with high accuracy, outperforms serum creatinine in kidney transplant recipients, and is highly sensitive in distinguishing ABMR from no ABMR. AlloSure is performed in the CareDx CLIA-certified laboratory. http://www.allosure.com/ About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients. http://www.allomap.com/
